Anti-viral and pro-inflammatory functions of Toll-like receptors during gamma-herpesvirus infections

Marta Maria Gaglia*

Abstract
Toll-like receptors (TLRs) control anti-viral responses both directly in infected cells and in responding cells of the immune systems. Therefore, they are crucial for responses against the oncogenic γ-herpesviruses Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus and the related murine virus MHV68, which directly infect immune system cells. However, since these viruses also cause lifelong persistent infections, TLRs may also be involved in modulation of inflammation during latent infection and contribute to virus-driven tumorigenesis. This review summarizes work on both of these aspects of TLR/γ-herpesvirus interactions, as well as results showing that TLR activity can drive these viruses’ re-entry into the replicative lytic cycle.

Keywords: Toll-like receptors, KSHV, HHV-8, EBV, MHV68, Gammaherpesvirus, Immune evasion

Introduction
The oncogenic human γ-herpesviruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) need to overcome the immune system’s protective responses to establish lifelong latent infections in patients and to intermittently re-enter the lytic cycle. While the ability to cause a latent infection allows these viruses to persist, the lytic replicative cycle is key for spread within and between hosts. Moreover, both types of infection are important for the development of γ-herpesvirus-linked diseases [1]. EBV infection is largely ubiquitous, but if acquired past childhood EBV often gives rise to infectious mononucleosis [2]. In a subset of infected individuals, EBV infection leads to the development of various types of B cell lymphomas, as well as specific subtypes of nasopharyngeal carcinoma (NPC) and gastric carcinoma [3]. In addition, EBV infection has also been linked to the development of autoimmune diseases [4]. KSHV infection is less prevalent, with a striking geographical bias, whereby seropositivity is much higher in Africa and some other regions of the world [5]. In some infected individuals, KSHV can give rise to Kaposi’s sarcoma and two B cell lymphoproliferative diseases, primary effusion lymphoma (PEL) and Multicentric Castleman disease (MCD), as well as KSHV-associated inflammatory cytokine syndrome (KICS) [3]. These diseases are predominantly found in immunosuppressed patients, although an endemic form of Kaposi’s sarcoma not clearly related to immunosuppression is also common in parts of Africa [5].

Infected cells are endowed with multiple mechanisms to sense the infection and initiate a local and systemic response. In turn, viruses have evolved a plethora of approaches to counteract and limit these responses. In this review, we will focus on the interactions between γ-herpesviruses and Toll-like receptors (TLRs), a class of membrane-associated pathogen-associated molecular pattern (PAMP) receptors that detects PAMPs in the extracellular space and in endosomes. Interestingly, while many studies have examined the anti-viral functions of TLRs in infectious mononucleosis and other herpesvirus infections, very little has been known about the role of TLRs in the establishment and maintenance of latent infections.
TLRs in γ-herpesvirus infections and viral TLR evasion strategies, interactions with TLR signaling are also relevant for other aspects of γ-herpesvirus biology (Fig. 1). Several studies suggest that TLR activation may be one of the triggers for lytic reactivation. Moreover, TLR modulation of inflammatory responses has been linked to tumorigenesis and autoimmunity, particularly during EBV infection. This review will summarize the current knowledge on these aspects of TLR biology during infection with the human viruses EBV and KSHV. I will also cover studies on the related murine herpesvirus 68 (MHV68). As EBV and KSHV do not infect mice, MHV68 is widely used as a small animal model virus for these infections, and is used to dissect γ-herpesvirus biology in vivo [6].

**Basics of TLR signaling**

Mammalian TLRs are a family of transmembrane pathogen-recognition receptors (10 in humans and 12 in mice) discovered in the mid-1990s (Fig. 2). They have leucine-rich repeat containing ectodomains and cytosolic Toll-IL-1 receptor (TIR) domains. They are named for their homology to the Toll protein in *Drosophila melanogaster*, which has roles in development. Different TLRs respond to different PAMPs (Fig. 2). However, they all trigger signaling pathways that culminate in the activation of the transcription factors NF-κB and/or interferon regulatory factor 3 and 7 (IRF3 and IRF7, Fig. 2). NF-κB induces transcription of pro-inflammatory cytokines like interleukin-6 (IL-6), while IRF3 and 7 induce transcription of type I interferons (IFNs), which are potent antiviral cytokines. In addition to responding to different cues, different TLRs have different localization, either at the plasma membrane or internal membranes, predominantly endoplasmic reticulum, endosomes and endolysosomes. Many of the internal TLRs respond to nucleic acids, which are not exclusively pathogen molecules. Their localization is thought to naturally limit the autoactivation of these TLRs by endogenous DNA and RNAs [7]. Despite many differences in signaling, all TLRs use one of two adaptor proteins to transduce their signaling – MyD88 or TRIF (Fig. 2). Both proteins contain TIR domains. Two additional adaptors, TRAM and TIRAP, are also involved in some of the signaling, although they are thought to act mostly as sorting adaptors, helping to recruit MyD88 and TRIF to the correct locale [7].

While intracellular PAMP-recognition receptors like RIG-I and cGAS are expressed in most if not all cell types, the expression of many TLRs is more restricted and they are found predominantly on cells of the immune system [8]. Because of this distribution, they have an important role in orchestrating organism-wide responses and modulating adaptive immunity [8]. In naïve B cells, which are the critical long term reservoir of EBV, KSHV and MHV68 infections, TLR activation promotes B cell activation [9], and may be sufficient for naïve B cell proliferation without B cell receptor ligation [10]. TLR stimulation, particularly CpG DNA activation of TLR9, also leads to proliferation in memory B cells [11] and increased antibody production in plasma cells [12].

Although activation of inflammatory cytokines and IFNs appears to be the main consequence of TLR activation, at least two TLRs, TLR3 and TLR4 have been reported to directly cause cell death [13, 14]. They do so by activation of caspase-8 through formation of a TRIF-containing signaling complex [13, 14]. However, this process has largely been described in response to purified TLR ligands and it remains unclear if and when it is invoked during pathogen infection.

**TLR signaling as anti-viral mechanism and evasion during γ-herpesvirus infection**

Because of the central role of TLRs in anti-viral responses, many studies have investigated which and how TLRs contribute to innate immune responses to γ-herpesviruses (Table 1). They have uncovered roles both in the infected cells themselves and in other cells of the immune system that are key to the response to infection, like monocytes and dendritic cells. TLR2, 7 and 9 (but not TLR3) are required for responses to MHV68 ex vivo in dendritic cells and in vivo [15–19]. However, TLR9 only has a role in protecting animals.
from MHV68 infection when MHV68 is administered from the intraperitoneal or intravenous route, not the intranasal route [16, 18, 19], possibly because TLR9 is not expressed in lung dendritic cells. Depending on the dose of the inoculum, loss of TLR9 in vivo can increase the number of latently infected cells in the spleen and/or the frequency of reactivation of lytic infection in these cells [16, 18, 19], both parameters that are important for tumor development in human herpesviruses. Consistent with the reports that TLRs sense and contribute to blocking MHV68 infection, MyD88 knockout mice were reported by Michaud et al. to have higher MHV68 infection rates [15]. However, a second study of MyD88 −/− mice reported instead that MyD88 loss impaired MHV68 infection, perhaps due to a role for MyD88 in B cell activation [17]. Possibly, these differences are linked to the dose of the inoculum, as proposed by Michaud et al. [15]. It is notable that inoculation doses used in the TLR studies summarized above vary by 2–3 orders of magnitude. The dynamics of the host response and/or the effect on different cell types may be different depending on the strength of the stimulus. In general, these studies highlight the complexity of the system, as TLR signaling occurs in both myeloid cells and B cells and can have different biological roles depending on the cell type.

The data available for anti-viral effects in KSHV and EBV infection are more limited. TLR9 also induces type I IFN responses in dendritic cells after KSHV and EBV infection [20–22]. It also mediates IL-17 secretion after peritoneal injection of EBV DNA in mice or ex vivo mouse monocyte treatment with EBV DNA [23]. TLR4 is activated during KSHV infection of lymphatic endothelial cells, the cells that give rise to KS, likely by the envelope glycoprotein [24]. Moreover, loss of TLR4 increases the susceptibility of these and other cell types to KSHV infection [24]. TLR2 signaling is activated by the EBV dUTPase BLFF3, likely secreted in extracellular vesicles (exosomes), and/or a virion component [21, 25–27], and TLR3 and 7 signaling are activated by Epstein–Barr
virus-encoded small RNAs (EBERs), likely also secreted by infected cells in exosomes [21, 22, 28]. Stimulation of these TLRs by EBV cues induces type I IFN and cytokine responses in monocytes and dendritic cells and promotes plasmacytoid dendritic cell maturation [21, 25–28]. The TLR mediated signaling in dendritic cells may be crucial to promote survival to infection through activation of NK and T cells, as shown by a study in a humanized mouse

| TLR | Localization and stimulus | Activated + protective role during infection? | Artificial stimulation blocks viral replication? | Activity or expression inhibited by infection? | Artificial stimulation triggers reactivation? |
|-----|--------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 1/2 | Cell surface; Diacyl lipopeptides (Pam3CSK4) | Activated – EBV [21, 26] Yes – MHV68 in vivo [15] | No – KSHV [35] No – EBV [31] Minor effect – MHV68 in cells [34] | Yes – EBV [44, 45] No – EBV [39] Yes – MHV68 in cells [42] | Yes – KSHV [62] Yes – EBV [67, 68] |
| 2/6 | Cell surface; Tricyclic lipopeptides (FSL-1) | Activated – EBV [21, 26] Yes – MHV68 in vivo [15] | No – KSHV [35] Minor effect – MHV68 in cells [34] | Yes – EBV [44, 45] No – EBV [39] | Yes – KSHV [62] Yes – EBV [67, 68] |
| 3   | Endosome; dsRNA (polyI:C) | Yes – MHV68 in vivo [17] Activated but aids viral replication – MHV68 in cells [56] | Yes – KSHV [35] | Dynamic changes – KSHV [41, 50] Yes – EBV [44] | No – KSHV [35] |
| 4   | Cell surface and endosome; LPS, lipidA | Yes – KSHV [24] No – EBV [26] No – KSHV [35] No – EBV [31] Yes – MHV68 [34] | Yes – KSHV [24] No – EBV [39] Yes – MHV68 in cells [43] | Yes – MHV68 ex vivo [63] No – KSHV [35] Yes (bacterial products) – KSHV [60] Maybe – EBV [68] Yes – MHV68 in cells, ex vivo, in vivo [63] |
| 5   | Cell surface; flagellin | Yes – KSHV [35] | Yes – EBV [44, 76] | No – KSHV [35] Yes – MHV68 in cells, ex vivo [63] |
| 7   | Endosome; ssRNA (sspolyU, imiquimod, R848) | Minor effect – EBV [21] Minor effect – MHV68 in cells and in vivo [16] | No – KSHV [35] No – EBV [31] Yes – MHV68 [34] | No – higher – KSHV [41] Yes – EBV [44, 45] | Yes – KSHV [35] |
| 8   | Endosome; ssRNA (sspolyU, R848) | Activated – EBV [80] | No – KSHV [35] No – EBV [31] | No – higher – KSHV [41] No – higher – EBV [80] Yes – MHV68 in cells [42] | Yes – KSHV [35] |
| 9   | Endosome; dsDNA (CpG) | Activated – EBV [22, 45] Yes – MHV68 in cells and in vivo [16, 18, 19] | No – KSHV [35] Yes – EBV [31–33] No – MHV68 in cells [34] | No – higher – KSHV [41] Yes – EBV [39, 44, 45] No – MHV68 in cells, ex vivo [63, 65] | Yes – KSHV [35] |
| 10  | Cell surface; Pathogen proteins? | Yes – EBV [39, 45] No – higher in transformed cells – EBV [72] | Yes – EBV [39, 45] | No – KSHV [35] |

Only studies using infectious viruses (not single proteins) are included. TLR2 can be found in complex with either TLR1 or TLR6. Hence, studies on TLR2 are cited for both complexes, as the responsible complex is not usually clear.
model of EBV [29]. Also, consistent with an important role for TLR signaling in EBV responses, a patient with a MyD88 mutation was reported to have persistent EBV viremia, albeit asymptomatic [30]. Like other data on the role of TLRs, these data point to a role for TLR signaling in protective responses against KSHV and EBV, and also highlight the range of signals from these viruses that can elicit a TLR response.

In addition to TLR activation by γ-herpesviruses, the anti-viral role of TLRs against these viruses is demonstrated by the fact that stimulation of TLRs reduces replication and reactivation of KSHV, EBV and MHV68 (Table 1). In particular, several studies have shown that TLR9 activation reduces EBV and MHV68 replication from a latent infection in B cells and EBV infection and/or replication in B cells and monocytes after a de novo infection [19, 21, 31–33]. The EBV studies did not test other TLR ligands, whereas Haas et al. also found an effect of TLR7 (but not TLR3) ligands on MHV68 activation in B cells [19, 31–33]. Seemingly in contrast with these results, Doyle et al. reported that TLR3 and TLR4 activation reduces MHV68 replication after de novo infection in bone marrow macrophages, whereas TLR9 activation in these cells has no effect [34]. However, the reported differences are most likely due to the expression levels of different TLRs and/or the downstream signaling that they elicit in the different cell types, as in macrophages TLR3/4 but not TLR9 stimulate type I IFN signaling [34]. In the case of KSHV, there may also be differences in the activity and role of TLRs depending on cell type. TLR4 activation reduces replication in endothelial cells infected de novo [24], while activation of TLR3 or TLR5 reduces spontaneous reactivation in PEL cells [35]. In addition to cytokine-based anti-viral responses, stimulation of TLR3 and 9 may also elicit another time of protective response, cell death, in latently EBV-infected cells, including some Burkitt’s lymphoma cell lines and NPC cells [36, 37]. In turn, EBV may counteract this pathway by inducing high levels of cellular inhibitor of apoptosis 2 (cIAP2) in some NPC cells, which protects them from TLR3-induced apoptosis [38]. While all these studies show a protective effect of TLR signaling, some studies suggest that TLR activation can actually increase γ-herpesvirus reactivation, which will be more extensively discussed in a later section.

If signaling from TLRs blocks γ-herpesvirus infection, it stands to reason that infection itself may modulate expression of these receptors. There are reports of both increase [15, 21, 39–41] and reduction of TLR expression and/or signaling [24, 39, 42–46] after infection with KSHV, EBV and MHV68 (Table 1). The direction of the detected changes depends on the virus, the cell type and the TLR studied. There are some discrepancies that are again likely to be linked to the normal function of the TLR and its ability to exert anti-viral activity in the specific cell type. Only a couple of the studies looked at more than one TLR in the same cells [39, 42, 45], so it is difficult to compare across studies. Moreover, multiple transformed B cells lines are used for KSHV and EBV studies, further complicating the picture. One consistent observation is the downregulation of TLR9 by EBV in B cells [39, 44, 45] and the reduction of signaling from multiple TLRs during MHV68 infection of macrophages and conventional dendritic cells [42, 43]. The effect of EBV on TLR9 is also consistent with the fact that activation of this TLR reduces EBV replication [21, 31–33]. Reports of reduction in TLR expression and/or signaling by γ-herpesviruses are also generally consistent with the poor responses of many cells to these viruses [42, 43], and suggest that these viruses have evolved evasion mechanisms to deal with TLR activation. Indeed, several viral proteins have been implicated in inhibition of TLR signaling: for KSHV, the master lytic regulator ORF50/RTA [42, 47–49], the virus interferon regulatory factor-like (vIRF) proteins K9/vIRF1 [50], K11/vIRF2 [50], K10.5/vIRF3 [42], the viral macrophage inflammatory protein III K4.2 [42], the viral thymidine kinase ORF21 [42], the regulators of viral gene expression ORF31 [42] and ORF57/MTA [51] and the KSHV microRNAs, particularly miR-K5 and miR-K9 [52]; for EBV, the non-coding EBER RNAs [53], the latent protein LMP1 [44], the deubiquitinase BPLF1 [54], and the host shutoff protein BGLF5 [45, 55]. These proteins and RNAs act through a variety of mechanisms. Some may alter the levels and localization of TLRs [21, 42, 45, 55] or of downstream signaling molecules like MyD88 and interleukin 1 receptor-associated kinase 1 (IRAK1) [47–49, 52]. Others may inhibit signal transduction downstream of TLR, for example through deubiquitination of signaling proteins [54]. Of note, some of the genes in the list above have homologs across the γ-herpesviruses (the regulators of gene expression ORF50/RTA/BRLF1, ORF57/MTA/BMLF1/SM, and ORF31/BDLF4, the viral thymidine kinase ORF21/vTK/BXLF1, the host shutoff protein ORF37/Sox/BGLF5, and the deubiquitinase ORF64/BPLF1). While these genes share other functions across the viruses, they were only identified in one of the viruses as TLR inhibitors. This could represent a different virus-specific function, or may simply be a limitation of the current studies. For example, to my knowledge no systematic screen of EBV or MHV68 proteins for TLR inhibition has yet been published, precluding a direct comparison with the KSHV results [42]. Lastly, in addition to these active mechanisms of TLR inhibition, Pezda et al. suggested that the paucity of CpG sequences in the MHV68 genome may also be responsible for reducing the TLR9 responsivity, as it reduces the viral DNA sequences that TLR9 can
recognize [43]. Nonetheless, this and other studies have also reported TLR9-dependent responses to MHV68, particularly in plasmacytoid dendritic cells [16, 18, 43], potentially because there is less viral replication in these cells and thus less expression of TLR inhibiting factors [43].

Interestingly, a recent study reports an even more complicated interaction between MHV68 and TLR signaling, whereby MHV68 takes advantage of TLR3 signaling to evade other immune responses. Shen et al. found that in MHV68-infected bone marrow-derived macrophages, TLR3 responses result in increased SOCS1 expression, which protects MHV68 from the anti-viral effects of IFN-γ treatment [56]. Along similar lines, TLR activation in EBV infected monocytes induces programmed death-ligand 1 (PD-L1) expression [57]. As PD-L1 reduces susceptibility to killing by cytotoxic T cells, it may protect the EBV-infected monocytes [57].

While collectively the reviewed studies point to a role for TLRs in the host protective response to γ-herpesviruses, the exact effects reported differ among the viruses and in some cases in studies using the same viruses. Since the pattern of TLR expression changes depending on the cell type and in some cases the signals elicited by TLR activation are also different, many of the apparent discrepancies are likely due to differences in the experimental setup. Discrepancies in MHV68 mouse studies are more puzzling but may be at least in part due to the choice of route of infection and inoculum size. Despite the remaining questions, it is clear that multiple TLRs protect humans and mice against γ-herpesviruses, acting both in the infected cells and of the innate immune cells that respond to the infection. Further studies, particularly systematic comparisons of the same TLR in different cell types and different TLRs in the same cell type, are needed to fully dissect the contributions of TLRs in protective responses to γ-herpesviruses.

**TLR signaling as a trigger for lytic reactivation of γ-herpesviruses**

In infected individuals or model organisms, EBV, KSHV and MHV68 undergo recurrent reactivation to the lytic cycle. This process has been linked to tumor development [1, 58, 59]. The cues that stimulate reactivation are only partially known, but they are generally thought to encompass many signals that trigger the death of the infected cells. The viruses are thought to have evolved to detect conditions that will lead to the death of the latently infected cells, and to respond by re-entering the lytic cycle, so that newly formed virions can infect new cells and the virus can continue to propagate. Interestingly, several studies have suggested that TLR activation can constitute a signal that triggers lytic replication in KSHV, EBV and MHV68 (Table 1). Indeed bacterial products were shown several years ago to induce lytic reactivation of KSHV in cell culture and MHV68 in an ex vivo setting, likely by stimulating TLRs [60, 61]. A recent study suggests that production of reactive oxygen species downstream of TLR2 may mediate this effect in the oral cavity following *Staphylococcus aureus* infections [62]. Gargano et al. also showed that well-characterized ligands for TLR3, 4, 5 and 9 can induce MHV68 reactivation from latently infected B cells in culture, in explanted splenocytes, and even in vivo [63]. This effect did not extend to other TLRs despite similar downstream signaling. Lytic infection is stimulated after TLR stimulation because the treatment induces activation and proliferation of the B cells [63]. This effect is similar to that of B cell receptor ligation, which also induces MHV68 and EBV reactivation [61, 64]. Interestingly, in mice TLR-induced reactivation leads to an increase in the population of latently MHV68-infected cells [63]. The authors attributed this increase to increased viral production and seeding of new infections, and speculated that this may be a way in which the latent reservoir is maintained in the presence of heterologous infections [63]. However, a later study suggested that the MHV68 latent reservoir could be expanded after TLR9 stimulation also in the absence of active replication [65]. In KSHV-infected PEL cells, stimulation of the TLR7/8 with single-stranded polyU and other artificial ligands or vesicular stomatitis virus infection induces lytic reactivation [35]. Although multiple other TLRs are expressed in PEL cells, this study did not detect significant increases in lytic reactivation after activation of other TLRs [35]. Nonetheless, another group found that TLR3 activation directly increases RTA expression in a transfection setting [66], suggesting other TLRs may induce KSHV lytic reactivation in other conditions. In the case of EBV, virus reactivation and EBV-linked hepatitis were reported in a patient with infection with the syphilis pathogen *Treponema pallidum*, a known inducer of TLR2 [67]. In addition, stimulation of multiple TLRs can induce expression of the lytic regulator ZEBRA in EBV latently infected cell lines [68]. Collectively, these studies underscore the multiplicity of functions that TLR signaling can have during γ-herpesvirus infection, including a role in promoting lytic replication. As TLR signaling can act as an activating stimulus for B cell, this positive effect on reactivation may be particularly pronounced in B cells, where reactivation is also coupled to other activating stimuli.

**TLR signaling and inflammation in connection to cancer and other diseases caused by EBV and KSHV**

Although much of the research on TLR and γ-herpesviruses has focused on their antiviral roles, another aspect of TLR signaling is the regulation of
inflammation. Inflammation has been connected to disease progression and cancer development in both EBV and KSHV infections. Moreover, TLRs regulate B cell responses, proliferation and antibody secretion [9–12], which means that TLR stimulation could promote viral persistence and expansion of infected cells. Indeed, TLR9 inducing cues have been used to improve immortalization of EBV infected B lymphocytes in cell culture [69]. Moreover, in experimental de novo EBV infections treatment with TLR ligands increased EBV-driven B cell activation and proliferation [70, 71]. Some reports also suggest that EBV-transformed B cells express more TLR9 and TLR10 [72], although other reports found the opposite [39]. The EBV oncoproteins LMP1 and LMP2A can also increase expression and responses of subset of TLRs, which provides a survival advantage to B cells and NPC cells, although these studies were done using over-expression and not EBV infection [73, 74]. In the context of NPC, the EBERs may induce TLR3 expression and cytokine-driven responses to promote tumorigenesis, as TLR3 knockdown reduces formation of NPC tumors in nude mice [75]. However, the relationship between TLR signaling and tumorigenesis may be more complex than these studies suggest. For example, a study of Finnish patients with NPC found that the low levels of TLR7 and 9 were correlated with worse disease outcomes, while lower levels of TLR5 were correlated with better outcomes [76].

Data on TLR and tumorigenesis in KSHV is limited. In a model of KSHV transformation using rodent mesenchymal stem cells, TLR4 activity was linked to increased proliferation, cytokine secretion and tumorigenesis in mouse xenografts [77]. Moreover, these KSHV-immortalized cells had increased TLR4 and MyD88 levels, suggesting the virus actively promotes their induction in the process of tumorigenesis [77]. Another potential connection between TLR signaling and KSHV tumors was identified in PEL cells, where Yang et al. reported that interleukin 1 receptor-associated kinase 1 (IRAK1), which acts downstream of TLRs, promotes PEL cell survival and is commonly mutated in PEL samples [78]. Moreover, MyD88/IRAK signaling is constitutively active in PEL cells [79].

EBV infection may also contribute to the development of autoimmune diseases [4]. The effect of EBV infection in autoimmunity has been linked to increased IFN responses downstream of TLR activation in some studies of scleroderma [46, 80], myasthenia gravis [81] and lupus [82]. In particular, TLR7 activation in EBV-transformed B cells may potentiate both LMP1 expression and responses to agonists of other TLRs, amplifying inflammation and potentially contributing to pathology in lupus patients [82].

Many of the studies on cancer and autoimmune disease modulation by TLR in the context of γ-herpesviruses show that these effects are mediated by increased TLR levels or signaling. This may seem paradoxical, since increased TLR activation would be expected to help clear infections. A potential explanation for these observations is that while activation of TLR early in γ-herpesvirus infection of a new host or during lytic reactivation has an antiviral function (see earlier section), activation of this pathway once latency has been established may promote disease progression. This could occur as a result of inflammatory cytokine expression, or because reactivation is blocked, favoring persistence of the latently infected cells.

Genetic associations between TLR polymorphisms, γ-herpesvirus infection and γ-herpesvirus-linked diseases

Several studies have identified polymorphisms in TLRs that modify susceptibility to immune and infectious diseases [83, 84]. In the context of γ-herpesviruses, there have been positive and negative findings on the connection between TLR polymorphisms and susceptibility to EBV infection and disease. In general, single-nucleotide polymorphisms that reduce TLR activity or expression were found to increase infection and/or disease risk in these studies. Polymorphisms in the TLR9 coding region or promoter have been linked to metrics of EBV infection and disease in various patient groups. These include risk of EBV infection, levels of EBV in the blood, development of infectious mononucleosis, development of oral cancers, NPC tumor size and survival of NPC patients [85–88]. Polymorphisms in the TLR4 coding region and 3′ UTR have also been reported to modify risk of infectious mononucleosis, NPC and oral cancers [85, 88, 89]. In addition, in one study polymorphisms in TLR2 affected the levels of EBV DNA in the blood of infectious mononucleosis patients and the development of specific symptoms [85]. In contrast, a study of Northern Chinese gastric carcinoma patients found no connection between known polymorphisms in TLR2, 3 and 9 and susceptibility to EBV-associated gastric carcinoma [90].

Less in known about the connection of TLR polymorphisms and KSHV infection and diseases. Two studies investigated the TLR4 Asp299Gly polymorphism and found it is more common in HIV-positive patients with MCD than ones with KS or cancers unrelated to KSHV [24], and it is also more frequent in patients of African descent [91]. MCD development may be linked to poorer control of KSHV replication, as these patients also had higher viremia [24, 91]. This is consistent with the fact that the Asp299Gly sequence change results in lower level of TLR4 at the plasma membrane and lower
LPS-triggered IFN induction [24, 91]. However, a recent genome-wide association study for both EBV and KSHV infection in an African cohort did not identify any TLR genes among their hits [92].

Conclusions
EBV, KSHV and MHV68 all interact with TLRs during the course of infection, particularly as they infect cells of the immune system that express multiple TLRs. Multiple components of these viruses appear to be recognized by different TLRs, including both proteins and nucleic acids (Fig. 2). As illustrated in this review, there is extensive evidence that TLRs can act in anti-viral fashion against γ-herpesviruses. However, TLR activation can also control the latent-lytic switch in B cells, acting to promote viral replication. Moreover, TLR activity may be connected to tumorigenesis and development of autoimmune diseases in response to γ-herpesvirus infection, because of the key role of TLRs in modulating inflammatory responses. These findings suggest that modulation of TLR signaling could be used as a potential therapeutic intervention for EBV or KSHV, perhaps combined with other treatments. However, leveraging the role of TLR will require a much more precise and comprehensive understanding of the role of specific key TLRs in the dynamics of infection and disease. Currently, there are inconsistencies in the literature that need to be resolved within the study of each of the three viruses reviewed here. Many of these inconsistencies may stem from complex biology of TLRs and the multiple functions these receptors have in different cell types. However, this remains to be thoroughly tested by comparing the effects of different TLRs in different cell types in a systematic fashion. In addition, there are contradicting results in the in vivo infection results with MHV68. The in vivo MHV68 infection system is currently the best small animal model for γ-herpesviruses, and the only one available to examine the effect of TLRs at different stages of infection in a whole organism. A more systematic comparison of TLR activation and function at different inoculum doses would begin to address potential confounds in this system. Additional studies like these may point to the potential usefulness of TLR agonists and antagonists for anti-viral and/or anti-tumor therapies.

Abbreviations
cGAS: Cyclic GMP-AMP synthetase; cIPAP2: Cellular inhibitor of apoptosis 2; EBERs: Epstein–Barr virus-encoded small RNAs; EBV: Epstein Barr virus; IFN: Interferon; IL-6: Interleukin 6; IRAK1: Interleukin 1 receptor-associated kinases 1; IRF: Interferon regulatory factor; KICS: Kaposi’s sarcoma-associated herpesvirus-associated inflammatory cytokine syndrome; KS: Kaposi’s sarcoma; KSHV: Kaposi’s sarcoma-associated herpesvirus; LMP: Latent membrane protein; LPS: Lipopolysaccharide; MCD: Multicentric Castleman Disease; MHV68: Murine herpesvirus 68; MTA: mRNA transcript accumulation; MyD88: Myeloid differentiation primary response 88; NPC: Nasopharyngeal carcinoma; NF-kB: Nuclear factor κ-light-chain-enhancer of activated B cells; pDC: Plasmacytoid dendritic cells; PD-L1: Programmed death-ligand 1; PAMP: Pathogen-associated molecular pattern; PEL: Primary effusion lymphoma; polyIC: polyinosinic-polycytidylic acid; RIG-I: Retinoic acid-inducible gene I; RTA: Replication and transcription activator; Spoly(U): Single-stranded polynucleotides; TLR: Toll-like receptor; TRAM: TRIF-related adaptor molecule; TRIF: TIR-domain-containing adapter protein inducing interferon-β; vIRF: Viral interferon regulatory factor.
Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36:6910–6.

Jang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2007;37:2205–13.

Bernaconi NL, Traggiai E, Lanzavecchia A. Maintenance of Sero- logical Memory by polyclonal activation of human memory B cells. Science. American Association for the Advancement of Science; 2002;298:2199–202.

Dorner M, Brandt S, Tingueylu M, Zucol F; Bourquin J-P; Zauner L, et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology. 2009;128:573–9.

Estones Y, Toscano F, Virad F, Jacquemin G, Pierrot A, Vanbervliet B, et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ. 2012;19:1482–94.

Feoisttistova M, Geserek P, Kellert B, Dimitrova DP, Langalis C, Hupe M, et al. cIAPs block ribosome formation, a RIP1/Caspase-8-containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43:449–63.

Michaud F, Coulombe F, Gaudeul F, Kriz J, Gosselin J. Involvement of TLR2 in recognition of acute gamma herpesvirus-68 infection. PLOS ONE. Public Library of Science; 2010;5:e13742.

Bussey KA, Murthy S, Reimer E, Chan B, Hatesuer B, Schughart K, et al. Endosomal toll-like receptors 7 and 9 cooperate in detection of murine gamma herpesvirus 68 infection. J Virol (Internet). American Society for Microbiology Journals; 2019 [cited 2021 Feb 7];93. Available from: http://jvi.asm.org/content/93/6/e01173-18.

Gargano LM, Moser JM, Speak SH. Role for MyD88 signaling in murine gamma herpesvirus 68 Latency. J Virol. Am Soc Microbiol J; 2008;82:3853–63.

Guggemoos M, Hangel D, H attr, B, Bauer S, Adler H. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37:2205–13.

Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. J Exp Med 2009;206:2091–9.

Lim WH, Kireta S, Russ GR, Coates PTH. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood. 2006;109:1045–50.

Chirico M, Di Matteo G, Conti F, Petricone D, De Luca M, Di Cesare S, et al. First Case of Patient With Two Homozygous Mutations in MYD88 and CARD9 Genes Presenting With Pyogenic Bacterial Infections, Elevated IgE, and Persistent EBV Viremia. Front Immunol (Internet); Frontiers; 2019 [cited 2021 Jun 14];10. Available from: http://www.frontiersin.org/articles/https://doi.org/10.3389/fimmu.2019.01030/full.

Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M, et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol. 2007;9:2055–69.

Jordi M, Marty J, Mordasini V, Lünenmann A, McComb B, Bernasconi M, et al. IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus (BLZLF1) transcription in Akata Burkitt’s lymphoma cells. PLOS ONE. Public Library of Science; 2017;12:e018654.

Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, et al. TLR9 triggering in Burkitt’s lymphoma cells lines suppresses the EBV BLZF1 transcription via histone modification. Oncogene Nature Publishing Group; 2010;29:4588–98.

Doyle SE, Vaidya SA, O’Connell R, Doggessler H, Dempsey PW, Wu T-T, et al. IRF3 Mediates a TLR3/TLR4-Specific Antiviral Gene Program. Immunity. 2002;7:1725–63.

Gregory SM, West JA, Dillon PJ, Hilischer C, Dittmer DP, Damania B. Toll-like receptor signaling controls reactivation of KSHV from latency. PNAS Natl Acad Sci. 2009;106:11725–30.

Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tingueylu M, et al. TLR9 agonists induced cell death in Burkitt’s lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis Nature Publishing Group; 2012;3:e323–e323.

Véniallau B, Grossset M, Morel Y, Paturel C, Herman P, Lo K-W, et al. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A)U combined to a Smac-mimetic. Infect Agents Cancer BioMed Central; 2012;7:10–10.

Ou C, Sun Z, Zhang H, Xiong W, Ma J, Zhou M, et al. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-κB pathway. Oncol Rep Spandidos Publ J; 2015;33:2779–88.

West J, Damania B. Upregulation of the TLR3 Pathway by Kaposi’s sarcoma-associated herpesvirus during primary infection. J Virol. Am Soc Microbiol J; 2008;82:5440–9.

Bussey KA, Reimer E, Todt H, Denker B, Gallo A, Konrad A, et al. The gamma-herpesviruses Kaposi’s sarcoma and murine gammaherpesvirus 68 modulate the toll-like receptor-induced proinflammatory signaling pathway. J Immunol Am Assoc Immunol J; 2015;185:6439–47.

Farina A, Cione M, York M, Lenna S, Padilla C, Mclaughlin S, et al. Epstein-Barr virus infection induces aberrant TLR activation pathway and delay EBV-related mortality in humanized NOD-SCID mice. Blood. 2007;81:9748–58.

Pezda AC, Penn A, Barton GM, Coscoy L. Suppression of TLR9 immunostimulatory motifs in the genome of a gammaherpesvirus. J Immunol. 2011;187:887–96.

Fathallah I, Parroche P, Guffaut H, Zannetti C, Johansson H, Yue J, et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol Am Assoc Immunol J; 2010;185:6439–47.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IGJ, Buisson M, et al. KSHV-membrane protein 1 Is a negative regulator of TLR9. J Immunol. Am Assoc Immunol J; 2014;188:415–27.

Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tingueylu M, et al. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis Nature Publishing Group; 2012;3:e323–e323.

Martin HJ, Lee JM, Walls D. Hayward SD. Manipulation of the Toll-like Receptor 7 signaling pathway by Epstein-barr virus. J Virol. 2007;81:9748–58.

Ou C, Sun Z, Zhang H, Xiong W, Ma J, Zhou M, et al. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-κB pathway. Oncol Rep Spandidos Publ J; 2015;33:2779–88.

West J, Damania B. Upregulation of the TLR3 Pathway by Kaposi’s sarcoma-associated herpesvirus during primary infection. J Virol. Am Soc Microbiol J; 2008;82:5440–9.

Bussey KA, Reimer E, Todt H, Denker B, Gallo A, Konrad A, et al. The gammaherpesviruses kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the toll-like receptor-induced proinflammatory cytokine response. J Virol. Am Soc Microbiol J; 2014;88:9245–95.

Pezda AC, Penn A, Barton GM, Coscoy L. Suppression of TLR9 immunostimulatory motifs in the genome of a gammaherpesvirus. J Immunol. 2011;187:887–96.

Fathallah I, Parroche P, Guffaut H, Zannetti C, Johansson H, Yue J, et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol Am Assoc Immunol J; 2010;185:6439–47.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IGJ, Buisson M, et al. EBV lytic phase protein BGLFS contributes to TLR9 downregulation during productive infection. J Immunol. 2011;186:1694–702.

Farina A, Cione M, York M, Lenna S, Padilla C, McLaughlin S, et al. Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol. 2014;134:954–64.

Zhao Q, Liang D, Sun R, Jia B, Xia T, Xiao H, et al. Kaposi's Sarcoma-associated herpesvirus-encoded replication and transcription activator impairs innate immunity via ubiquitin-mediated degradation of myeloid differentiation factor 88. J Virol. Am Soc Microbiol J; 2015;89:415–27.
48. Lingel A, Ehlers E, Wang Q, Cao M, Wood C, Lin R, et al. Kaposi’s sarcoma- associated herpesvirus reduces cellular myeloid differentiation primary- response gene 88 (MyD88) expression via modulation of its RNA. J Virol. Am Soc Microbiol J; 2016;90:180–8.
49. Ahmad H, Gubbels R, Ehlers E, Meyer F, Waterbury T, Lin R, et al. Kaposi sarcoma-associated herpesvirus degrades cellular toll-interleukin-1 receptor domain-containing adaptor-inducing β-interferon (TRIF). J Biol Chem. 2011;286:7865–72.
50. Jacobs SR, Gregory SM, West JA, Wollish AC, Bennett CL, Blackbourn DJ, et al. The viral interferon regulatory factors of kaposi’s sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3. J Virol. Am Soc Microbiol J; 2013;87:798–806.
51. Sharma NR, Majerciak V, Kruhlik MJ, Zheng Z-M. KSHV inhibits stress granule formation by viral ORF57 blocking PKR activation. PLOS Pathogens. Public Library of Science; 2017;13(1):e1006677.
52. Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegel- bauer JM. Kaposi’s sarcoma-associated herpesvirus MicroRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol. Am Soc Microbiol J; 2012;86:1663–74.
53. Wong HL, Wang X, Chang RC-C, Jin D-Y, Feng H, Wang Q, et al. Stable Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegel- bauer JM. Kaposi’s sarcoma-associated herpesvirus MicroRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol. Am Soc Microbiol J; 2012;86:1663–74.
54. van Gent M, Wollish AC, Bennett CL, Blackbourn DJ, et al. The viral interferon regulatory factors of kaposi’s sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3. J Virol. Am Soc Microbiol J; 2013;87:798–806.
55. Jabłońska A, Studzińska M, Szenborn L, Wiśniewska-Ligier M, Karlikowska- Skwarnik M, Gęsicki T, et al. TLR4 896A/G and TLR9 1174G/A polymor- phisms in Autoimmune Disease. Front Immunol [Internet]. Frontiers; 2021[cited 2021 Jul 1];12. Available from: http://www.frontiersin.org/article/10.3389/fimmu.2021.672346/full.
56. Galadini Montani MS, Santarelli R, Falcinelli L, Gonnella R, Granato M, Boer I, et al. Kaposi’s sarcoma-associated herpesvirus MicroRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J Virol. Am Soc Microbiol J; 2012;86:1663–74.
57. Sheny W, Wang S, Sun F, Zheng G, Wu T, Du Y, et al. Inhibition of murine herpes- virus-6 replication by IFN-gamma in macrophages is counteracted by the induction of SOCS1 expression. PLOS Pathogens. Public Library of Science; 2017;14:e1007202.
58. Tarakanova VL, Suarez F, Tibbetts SA, Jacoby MA, Weck KE, Hess JL, et al. Kaposi sarcoma-associated herpesvirus degrades cellular toll-interleukin-1 receptor domain-containing adaptor-inducing β-interferon (TRIF). J Biol Chem. 2011;286:7865–72.
59. Cowan NJ, Stone CO, Giorgi JV, Deacalogiannis P, Kekos EG, Kersky JL, et al. Epstein-barr virus large tegument protein bplf1 contributes to innate response gene 88 (MyD88) expression via modulation of its RNA. J Virol. Am Soc Microbiol J; 2012;86:1663–74.
60. Morris TL, Arnold RR, Webster-Cyriaque J. Signaling cascades triggered by bacterial metabolic end products during reactivation of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2007;81:6032–42.
61. Moser JM, Upton JW, Gray KS, Speck SH. Ex vivo stimulation of B cells points to (innate) targets for immune evasion. J Gen Virol. 2015;96:858–65.
62. Dai L, Qiao J, Yin J, Goldstein A, Lin H-Y, Post SR, et al. EBV up-regulates PD-L1 on the surface of primary monocytes by the induction of SOCS1 expression. PLOS Pathogens. Public Library of Science; 2017;13:e1006677.
63. Bourke E, Bossio D, Goly J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102:956–63.
64. Zhou L, Hang X, Xie L. Toll-like receptor 3 (TLR3) functions as a pivotal driver for Kaposi sarcoma-associated herpesvirus. J Virol. Am Soc Microbiol J; 2016;90:180–8.
65. Iskra S, Kalla M, Deleacluse H-J, Hammerschmidt W, Moosmann A. Toll-Like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-barr virus. J Virol. 2010;84:3612–23.
66. Siennicka J, Trzcińska A, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–5.
67. Iskra S, Kalla M, Deleacluse H-J, Hammerschmidt W, Moosmann A. Toll-Like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-barr virus. J Virol. 2010;84:3612–23.
68. Yusen E, Shirazi FG, Memarian A, Amanzadeh A, Jeddii-Tehrani M, Shokri F. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay. Cytotecnology. 2014;66:95–105.
69. Gruffaz M, Vasan K, Tan B, Silva SR da, Gao S-J. TLR4-Mediated Inflamma- tion Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway. Cancer Res. American Association for Cancer Research; 2017;77:7094–108.
70. Wu Y, Zhang X, Xie L. Toll-like receptor 3 (TLR3) functions as a pivotal driver for Kaposi sarcoma-associated herpesvirus. J Virol. 2005;79:14686–79.
71. Yosra M, Sameh S, Randa G, Yassmine R, Sallouha G, Nadia B, et al. Functional polymorphisms and gene expression of TLR9 gene as protective receptor 2 and B-Cell receptor activation. Open Forum Infectious Dis- eases. 2019. https://doi.org/10.1093/ofid/ofz317.
72.Sanders JW, Moors AJ, Coucke P, Glaudemans A, Schellekens H, Aerts J, et al. Kaposi’s sarcoma-associated herpesvirus infection is associated with increased expression of Toll-like receptor 7 and 9 in myasthenia gravis patients. J Neuroimmunol. 2014;262:147–55.
73. Muller R, Ehlers E, Meyer F, Waterbury T, Cao M, Zhang L. TLR-TRIF pathway enhances the expression of KSHV replication and transcription activator. J Biol Chem. 2013;288:20435–42.
74. Valente RM, Ehlers E, Xu D, Ahmad H, Steadman A, Blasnitz L, et al. Toll-like receptor 7 stimulates the expression of epstein-barr virus latent membrane protein 1. PLOS ONE. Public Library of Science; 2012;7:e43317.
75. Mukherjee S, Huda S, Babu SPS. Toll-like receptor polymorphism in host response. Open Forum Infectious Dis- eases. 2019. doi:10.1093/ofid/ofz317.
76. Siennicka J, Trzcińska A, Cieszkic A, Dubal-Szczepaniak M, Lagoz B. The influence of toll-like receptor stimulation on expression of EBV lytic genes. Pol J Microbiol. 2013;62:237–42.
77. Gruffaz M, Vasan K, Tan B, Silva SR da, Gao S-J. TLR4-Mediated Inflamma- tion Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway. Cancer Res. American Association for Cancer Research; 2017;77:7094–108.
78. Yang D, Chen W, Xiong J, Sherrod CJ, Henry DH, Dittmer DP. Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. PNAS National Academy of Sciences. 2014;111:E4762–8.
79. Zeng X, Cao M, Wang S, Sun F, Zheng G, Wu T, Du Y, et al. Inhibition of murine herpesvirus-6 replication by IFN-gamma in macrophages is counteracted by the induction of SOCS1 expression. PLOS Pathogens. Public Library of Science; 2018;14:e1007202.
80. Iskra S, Kalla M, Deleacluse H-J, Hammerschmidt W, Moosmann A. Toll-Like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-barr virus. J Virol. 2010;84:3612–23.
81. Dzialdowski M, et al. EBV up-regulates PD-L1 on the surface of primary monocytes by the induction of SOCS1 expression. PLOS Pathogens. Public Library of Science; 2017;13:e1006677.
factors for nasopharyngeal carcinoma severity and progression. J Immunol Res. Hindawi; 2019;2019:e2826563.

87. Beima-Sofie K, Wamalwa D, Maleche-Obimbo E, Lingappa JR, Mackelprang R, Gantt S, et al. Toll-like receptor 9 polymorphism is associated with increased Epstein-Barr virus and Cytomegalovirus acquisition in HIV-exposed infants. AIDS. 2018;32:267–70.

88. Sharma U, Singhal P, Bandil K, Patle R, kumar A, Neyaz K, et al. Genetic variations of TLRs and their association with HPV/EBV, co-infection along with nicotine exposure in the development of premalignant/malignant lesions of the oral cavity in Indian population. Cancer Epidemiol. 2019;61:38–49.

89. Song C, Chen L-Z, Zhang R-H, Yu X-J, Zeng Y-X. Functional variant in the 3'-untranslated region of toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Therapy. Taylor & Francis; 2006;5:1285–91.

90. Liu S, Wang X, Shi Y, Han L, Zhao Z, Zhao C, et al. TLR-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. Saudi Journal of Gastroenterology. 2015;21:95.

91. Westrop SJ, Lagos D, Boshoff C, Bower M, Imami N. African ancestry and innate immunity contribute to the incidence of multicentric Castleman’s disease in HIV-1/Kaposi’s sarcoma herpesvirus-coinfected individuals. Future Virology. London, United Kingdom: Future Med Ltd; 2012;7:729–34.

92. Sallah N, Miley W, Labo N, Carstensen T, Fatumo S, Gurdasani D, et al. Distinct genetic architectures and environmental factors associate with host response to the γ 2-herpesvirus infections. Nat Commun. Nature Publishing Group; 2020;11:3849.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.